 |
|
The release of new data from the HVTN 502 HIV vaccine study
November 08, 2007Statement of Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases
The new analyses revealed today from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. Analyses of the STEP data are continuing, and it will take some time before we fully understand these results.
NIAID and its study partners, Merck & Co., Inc., and the HIV Vaccine Trials Network (HVTN), fully recognize the importance of these results to the volunteers who participated in the study and the larger scientific community. We are committed to working together to better understand the data from this study, and disclosing new findings as they become available.
Certainly, the failure of this HIV vaccine product was unexpected. But this setback should not and can not diminish our commitment to developing an effective HIV vaccine. Every day, another 12,000 people become infected with HIV, most of whom live in resource-poor countries. Approximately, 40 million people are currently living with HIV infection, and more than 25 million people with AIDS have died. Last year alone, an estimated 4.3 million new HIV infections occurred worldwide.
Historically, vaccines have been the most effective weapon against infectious diseases, such as polio, measles, mumps and smallpox. The goal of developing a safe and effective HIV vaccine is a key goal of HIV research today. However, the complex and unique nature of HIV has presented a formidable challenge to developing an effective vaccine.
In the absence of an HIV vaccine, there are proven methods for preventing HIV transmission that we, as a global community, must implement on a wider scale. These methods include HIV/AIDS education and behavior modification; condom usage to prevent sexual HIV transmission; medically supervised adult male circumcision in appropriate settings; needle exchange programs to curb bloodborne HIV transmission among injection drug users; and the use of antiretroviral drugs in HIV-infected pregnant women to prevent mother-to-child HIV transmission. Although none of these interventions is completely effective on its own, when used in combination they can have a significant impact on HIV prevention. Less than 20 percent of the world's population currently has access to proven HIV prevention services, but this figure is growing with the efforts of programs such as the President's Emergency Plan for AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and many others.
In addition to existing HIV prevention tools, we must create new, evidence-based approaches to HIV prevention, such as topical anti-HIV gels or creams that could be applied prior to sexual intercourse; preventive regimens of antiretroviral medications; and, especially, a vaccine. A setback in a given clinical trial is no reason to lessen our commitment to tackling the scientific challenges inherent in this field of research. What we learn from the STEP study will inform ongoing and future HIV vaccine research.
We must regroup and recommit ourselves to developing an HIV vaccine and other new prevention weapons while providing proven HIV prevention tools to those who need them. In the global fight against the HIV/AIDS pandemic, every prevention tool is of paramount importance.
NIH/National Institute of Allergy and Infectious Diseases
Certainly, the failure of this HIV vaccine product was unexpected. But this setback should not and can not diminish our commitment to developing an effective HIV vaccine. Every day, another 12,000 people become infected with HIV, most of whom live in resource-poor countries. Approximately, 40 million people are currently living with HIV infection, and more than 25 million people with AIDS have died. Last year alone, an estimated 4.3 million new HIV infections occurred worldwide.
Historically, vaccines have been the most effective weapon against infectious diseases, such as polio, measles, mumps and smallpox. The goal of developing a safe and effective HIV vaccine is a key goal of HIV research today. However, the complex and unique nature of HIV has presented a formidable challenge to developing an effective vaccine.
In the absence of an HIV vaccine, there are proven methods for preventing HIV transmission that we, as a global community, must implement on a wider scale. These methods include HIV/AIDS education and behavior modification; condom usage to prevent sexual HIV transmission; medically supervised adult male circumcision in appropriate settings; needle exchange programs to curb bloodborne HIV transmission among injection drug users; and the use of antiretroviral drugs in HIV-infected pregnant women to prevent mother-to-child HIV transmission. Although none of these interventions is completely effective on its own, when used in combination they can have a significant impact on HIV prevention. Less than 20 percent of the world's population currently has access to proven HIV prevention services, but this figure is growing with the efforts of programs such as the President's Emergency Plan for AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and many others.
In addition to existing HIV prevention tools, we must create new, evidence-based approaches to HIV prevention, such as topical anti-HIV gels or creams that could be applied prior to sexual intercourse; preventive regimens of antiretroviral medications; and, especially, a vaccine. A setback in a given clinical trial is no reason to lessen our commitment to tackling the scientific challenges inherent in this field of research. What we learn from the STEP study will inform ongoing and future HIV vaccine research.
We must regroup and recommit ourselves to developing an HIV vaccine and other new prevention weapons while providing proven HIV prevention tools to those who need them. In the global fight against the HIV/AIDS pandemic, every prevention tool is of paramount importance.
NIH/National Institute of Allergy and Infectious Diseases
HIV Vaccine Current Events and HIV Vaccine News RSSNew findings suggest strategy to help generate HIV-neutralizing antibodies
New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Global challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.
New chemically-activated antigen could expedite development of HIV vaccine
Scientists working to develop a vaccine for the human immunodeficiency virus (HIV) report they have created the first antigen that induces protective antibodies capable of blocking infection of human cells by genetically-diverse strains of HIV.
Researchers induce HIV-neutralizing antibodies that recognize HIV-1 envelope protein, lipids
For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids.
College students who feel 'invincible' unlikely to accept vaccines, MU researcher finds
Vaccines to protect against sexually transmitted diseases, including HIV and herpes, are being developed and may soon be available to college students.
Penn-Wistar team gains insight into HIV vaccine failure
A team of researchers from The Wistar Institute and the University of Pennsylvania reports new evidence refuting a popular hypothesis about the highly publicized failure in 2007 of the Merck STEP HIV vaccine study that cast doubt on the feasibility of HIV-1 vaccines.
NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease.
New contraceptive device is designed to prevent sexual transmission of HIV
Researchers from Weill Cornell Medical College have published results showing that a new contraceptive device may also effectively block the transmission of the HIV virus.
Novel vaccine approach offers hope in fight against HIV
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
More HIV Vaccine Current Events and HIV Vaccine News Articles
 |
Shots in the Dark: The Wayward Search for an AIDS Vaccine by Jon Cohen (Author) "[A]n important book not only for the now but for the future of this epidemic and those to come."—Dr. Robert Gallo When scientists proved in 1984 that HIV causes AIDS, a vaccine race spun into action. But the sprint to develop an AIDS vaccine now more closely resembles a crawl. Jon Cohen elucidates the forces that have hindered the search: unforeseen scientific obstacles, clashing personalities, the uncertain marketplace, haphazard political organization, and serious ethical dilemmas. Beyond a powerful critique, Cohen also offers specific recommendations for accelerating the effort. 6 pages of b/w photographs.. |
|
The First Decade of Safe and Effective HIV Vaccines by Jeremiah O. A. Abalaka (Author) | |
 |
HIV And Molecular Immunity: Prospects for the AIDS Vaccine by Omar Bagasra (Author) How old is the AIDS virus (HIV-1) and where did it come from? Is it the result of a recombinant event in simian immunodeficiency viruses (SIVs)? Why do SIVs naturally occur in a variety of nonhuman African primates without inducing AIDS in their natural hosts? HIV-1 has devastated human society, although chimpanzees carry an SIV that is genetically almost identical to HIV-1 but causes no known illness in these great apes. How are Chimpanzees immune to HIV-1? Can humans acquire this immunity? Why do most newborns infected with HIV-1 in utero or during birth become long-term non-progressors while 20% rapidly develop AIDS and die in less than a year? Why are some adults asymptomatic for over 10 years after infection? Dr. Omar Bagasra, an eminent molecular biologist, immunologist,... |
 |
The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vaccine (Medical Ethics) by Christine Grady (Author) National Institute of Nursing Research. Single-author review of the current state of HIV vaccine research from the perspective of the ethical aspects of human subject research. |
|
Immune Response Bears Brunt of Partner's Pullout.(Agouron Pharmaceuticals will no longer fund development of its experimental HIV vaccine, Remune)(Brief ... An article from: San Diego Business Journal by Marion Webb (Author) This digital document is an article from San Diego Business Journal, published by CBJ, L.P. on July 16, 2001. The length of the article is 556 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Immune Response Bears Brunt of Partner's Pullout.(Agouron Pharmaceuticals will no longer fund development of its experimental HIV vaccine, Remune)(Brief Article) Author: Marion Webb Publication: San Diego Business Journal (Magazine/Journal) Date: July 16, 2001 Publisher: CBJ, L.P. Volume: 22 Issue: 29 Page: 9 Article Type: Brief Article Distributed by Thomson... | |
 |
HIV/Vaccine Needs - Procs of the Intl Seminar on Planetary Emergencies, 24th Session by Richard C. Ragaini (Author), Ragaini Richard (Author) This exploration of HIV/AIDS vaccine needs is taken from the 24th Session of the International Seminar on Nuclear War and Planetary Emergencies. Topics covered include: biotechnology; neuropathologies; development; sustainability; energy; water; and more. |
|
U.S. AWARDS $15 MIL TO GEOVAX HIV/AIDS VACCINE PROGRAM.: An article from: Biotech Business by Gale Reference Team (Author) This digital document is an article from Biotech Business, published by Thomson Gale on November 1, 2007. The length of the article is 573 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: U.S. AWARDS $15 MIL TO GEOVAX HIV/AIDS VACCINE PROGRAM. Author: Gale Reference Team Publication: Biotech Business (Newsletter) Date: November 1, 2007 Publisher: Thomson Gale Volume: 20 Issue: 11 Page: NA Distributed by Thomson... | |
|
Ethical Issues in HIV Vaccine Trials by Thomas A. Kerns (Author) | |
|
Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues (S. Hrg.) by United States (Other Contributor) | |
|
Wyeth enters into $32 million contract with NIH for ongoing HIV vaccine tesearch.: An article from: BIOTECH Patent News by Thomson Gale (Publisher) This digital document is an article from BIOTECH Patent News, published by Thomson Gale on November 1, 2005. The length of the article is 461 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Wyeth enters into $32 million contract with NIH for ongoing HIV vaccine tesearch. Publication: BIOTECH Patent News (Newsletter) Date: November 1, 2005 Publisher: Thomson Gale Volume: 19 Issue: 11 Distributed by Thomson Gale |
| © 2009 BrightSurf.com |